title: Screening of genetic and expression alterations of SRC1 gene in prostate cancer.
abstract: BACKGROUND
  Genetic alterations of the SRC1 gene have not been thoroughly studied in prostate cancer.
  
  
  METHODS
  Five prostate cancer cell lines and 32 xenografts were screened for mutations and gene copy number alterations. Subsequently, frequencies of detected sequence variations were further analyzed in 44 clinical prostate cancers, 6 benign prostate hyperplasias, and 48 normal controls. Finally, the protein expression of SRC1 in 254 clinical prostate tumors was investigated.
  
  
  RESULTS
  Three non-recurrent sequence variations, and one single nucleotide polymorphism in the coding region of SRC1, as well as one case of SRC1 gene amplification were found. The protein expression of SRC1 was higher in androgen ablation resistant than untreated prostate carcinomas, but the difference was not statistically significant (P = 0.0796).
  
  
  CONCLUSIONS
  Genetic alterations of SRC1 are rare in prostate cancer. The nuclear protein accumulation of SRC1 seems to be mildly increased in androgen ablation resistant prostate cancers. .
authors.affiliation: Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.
authors.forename: Hanna E
authors.initials: HE
authors.lastname: Mäki
authors.forename: Kati K
authors.initials: KK
authors.lastname: Waltering
authors.forename: Mika J
authors.initials: MJ
authors.lastname: Wallén
authors.forename: Paula M
authors.initials: PM
authors.lastname: Martikainen
authors.forename: Teuvo L J
authors.initials: TL
authors.lastname: Tammela
authors.forename: Wytske M
authors.initials: WM
authors.lastname: van Weerden
authors.forename: Robert L
authors.initials: RL
authors.lastname: Vessella
authors.forename: Tapio
authors.initials: T
authors.lastname: Visakorpi
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D016391:Genes, src / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods; D051548:Histone Acetyltransferases / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009154:Mutation / Q000235:genetics; D056920:Nuclear Receptor Coactivator 1; D021141:Nucleic Acid Amplification Techniques; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; D004273:DNA, Neoplasm; D014157:Transcription Factors; D051548:Histone Acetyltransferases; C538859:NCOA1 protein, human; D056920:Nuclear Receptor Coactivator 1